An interventional study of Tranexamic acid (intra-articular) and Tranexamic acid (intravenous) in Rotator Cuff Tears, sponsored by Konkuk University Medical Center. Completed at 1 site in South Korea. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Konkuk University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of — 3 open to participants now, 4 under way, 1 of them phase 3. Rotator Cuff Injuries · Korea, Republic of.
Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 17 with no phase, and was the 28th registered.
632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.
Browse Rotator Cuff Injuries studies →3 of the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–79
Eulji University Hospital · Sites in Korea, Republic of
Ages 18+
Tego Science, Inc. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 74 across the 25 interventional studies, 100 across the 5 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 30 have an industry lead sponsor. The 10 most frequent:
Konkuk University Medical Center is the lead sponsor of 95 studies on the registry; 15 are open to participants now.
Konkuk University Medical Center has 1 study filed under Rotator Cuff Injuries — fewer than ten, so there is no comparison to draw.
1 of the studies in Rotator Cuff Injuries with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07699744Seoul National University HospitalIntravenous Dexamethasone With Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain After Shoulder Surgery | 2027-06-15 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, prospective, randomized, double-blind controlled trial evaluated whether intravenous (IV) or intra-articular (IA) administration of tranexamic acid (TXA) improves intraoperative visual clarity, compared with a no-TXA control, during arthroscopic rotator cuff repair. Patients with rotator cuff tears were randomly allocated to one of three groups: a control group receiving no TXA; an IA group in which 500 mg of TXA was added to each 1 L of normal-saline irrigation fluid; and an IV group receiving 1000 mg of TXA intravenously 10 minutes before surgery. The operating surgeon graded visual clarity on a 0-10 numeric scale at the end of each of six predefined surgical stages. Secondary outcomes included total operative time, estimated blood loss, irrigation-fluid volume, the number of irrigation-pressure increases, postoperative shoulder swelling, and postoperative day 1 pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No tranexamic acid; arthroscopic rotator cuff repair performed with plain normal-saline irrigation.
Tranexamic acid 500 mg added to each 1 L of normal-saline irrigation fluid during arthroscopic rotator cuff repair.
Drug: Tranexamic acid (intra-articular)
Tranexamic acid 1000 mg administered intravenously 10 minutes before surgery; plain normal-saline irrigation as in the control group.
Drug: Tranexamic acid (intravenous)
500 mg of tranexamic acid added per 1 L of normal-saline irrigation fluid.
1000 mg of tranexamic acid administered intravenously 10 minutes before surgery.
Intraoperative visual clarity
Surgeon-rated clarity of the arthroscopic surgical field on a 0-10 numeric scale (0 = poorest visualization, 10 = optimal visualization), scored at the end of each of six surgical stages: glenohumeral procedure, subacromial bursectomy, acromioplasty, rotator cuff inspection, medial-row repair, and lateral-row repair.
Time frame: Intraoperatively, at the end of each of the six surgical stages
Total operative time
Total duration of the surgical procedure.
Time frame: Intraoperative (duration of surgery)
Estimated blood loss
Estimated blood loss calculated from serum hemoglobin measured before and after surgery using the formula described by Good et al.
Time frame: postoperative day 1
Irrigation-fluid volume
Total volume of irrigation fluid used during the procedure.
Time frame: Intraoperatively, from skin incision to skin closure (duration of surgery)
Number of irrigation-pressure increases
Number of times the irrigation pump pressure was increased to control bleeding affecting the surgical field
Time frame: Intraoperatively, from skin incision to skin closure (duration of surgery)
Postoperative shoulder swelling
Shoulder circumference and diameter measured at the axillary and deltoid sites with the arm abducted \~30 degrees, compared between pre-operative and postoperative day 1
Time frame: Baseline (pre-operative) and postoperative day 1
Postoperative pain
Pain assessed using a visual analog scale (VAS) on postoperative day 1
Time frame: Pain assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate worse outcome, on postoperative day 1
Plan to share: No — There is no plan to share individual participant data.
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Aug 2024, 15 months.
Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 15 months is below that.
Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start May 2022 → May 2023, primary completion Aug 2023 → Aug 2024 and completion Aug 2023 → Aug 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Konkuk University Medical Center